Abiopharma

🔍 Kaufman Daniel Louis (Executive)

Company: BranchOut Food Inc. (BOF)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Acquired 500,000 shares of Common Stock at $1.5 per share (Direct)
  Date: 2026-05-07 | Code: X | equity_swap_involved: 0 | shares_owned_after: 1,903,506.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 500,000 shares of Warrant at $1.5 per share (Derivative)
  Date: 2026-05-07 | Code: X | Expires: 2026-12-31 | Exercise: 2024-10-14 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2
• Holds 4,692,648 shares of Conv. Note (as amended) at $0.7582 per share (Derivative)
  Date: 2026-05-07 | Code: H | Expires: 2027-12-31 | Exercise: 2024-10-14 | shares_owned_after: 4,692,648.00 | Footnotes: F3, F4, F5, F5, F2

Footnotes:

• F1: Represents 1,903,506 shares of Common Stock held directly by Kaufman Kapital LLC following the May 5, 2026 sale of 255,951 shares and the May 7, 2026 exercise of the $1.50 Warrant for 500,000 shares (1,659,457 - 255,951 + 500,000 = 1,903,506).
• F2: Daniel L. Kaufman is the sole member and manager of Kaufman Kapital LLC and has sole voting and dispositive power over all securities held by Kaufman Kapital LLC.
• F3: On May 7, 2026, the Convertible Note was amended to (i) extend the maturity date from December 31, 2026 to December 31, 2027, (ii) reduce the interest rate from 12% to 8% per annum (effective from May 7, 2026; interest accrued prior to that date was calculated at 12%), and (iii) provide that the Company may not prepay more than $2,400,000 of principal prior to September 30, 2027 without the holder's consent. The conversion price ($0.7582 per share) and all conversion mechanics remain unchanged. Both outstanding principal ($2,900,000) and accrued and unpaid interest (approximately $658,100 as of the date hereof, calculated at 12% through May 7, 2026) are convertible at the option of the holder at any time.
• F4: Maturity date as amended on May 7, 2026. Prior maturity date was December 31, 2026. The Convertible Note became exercisable/convertible on October 14, 2024, the date of shareholder approval.
• F5: Represents approximately 4,692,648 shares of Common Stock issuable upon conversion of all outstanding principal ($2,900,000) and accrued and unpaid interest (approximately $658,100) under the Convertible Note at the conversion price of $0.7582 per share. Interest accrues at 8% per annum on $2,900,000 of outstanding principal following the May 7, 2026 amendment.